Vivos Inc. announced a significant expansion of its manufacturing footprint, securing a contract for production space at the Applied Process Engineering Laboratory (APEL) in Richland, Washington, and entering talks with Indian contract manufacturers to establish an international production site.
The Washington plant will produce Y‑90 phosphate particles and mix them with sterile hydrogel to create patient‑specific doses of RadioGel and IsoPet, serving as the company’s domestic hub and enabling automated production and higher throughput for both human and veterinary therapies.
Vivos will continue to use its Texas contract manufacturer through the second quarter of 2026 while the APEL site’s equipment is installed and licensed, with a transition to in‑house production expected by Q2 2026.
In parallel, the company is negotiating with Indian contract manufacturers to build an international facility that could be operational by the end of 2026. This effort is part of the Vivos Scientific India LLP entity formed in September 2025, aimed at reducing shipping costs and expanding global market access.
The expansion addresses a key risk identified in recent filings—reliance on a single production location—and positions Vivos to meet growing demand as it advances toward FDA IDE approval for RadioGel. A revised IDE submission is planned for the end of Q1 or April 2026, following a prior IDE rejection in August 2025.
Vivos’ veterinary portfolio continues to grow, with IsoPet reporting an 800% year‑over‑year increase in administered therapies in late 2025, while the human therapy remains in the regulatory review phase.
Financially, Vivos reported $1.99 million in cash and negative returns over the last 90 days, indicating significant investment needs for the new facilities. The expansion is viewed as a strategic move to reduce supply‑chain bottlenecks and improve margins over the long term.
Overall, the dual‑site strategy underscores Vivos’ commitment to scaling production, mitigating operational risk, and positioning the company for future growth in both human and veterinary markets.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.